Health Canada Reviews 9 Generic Semaglutide Applications for 2026
Health Canada is currently reviewing nine applications for generic versions of semaglutide, the active ingredient in Ozempic and Wegovy, with industry experts expecting the first approvals to emerge in the third quarter of 2026.
Timeline for Generic Approvals
Following the expiry of semaglutide's patent protection on January 4, 2026, pharmaceutical companies have submitted applications to produce generic versions of the medication. Sandoz, which initially aimed for a first-half 2026 launch, now expects the Canadian generic market to take shape in Q3 2026 according to reports from industry publications.
The regulatory timeline represents a significant development for Canadian patients and healthcare systems, as Ozempic and Wegovy currently cost between $400-$570 CAD monthly without insurance coverage.
Regulatory Review Process
Health Canada has confirmed it is working through the generic semaglutide applications as part of a broader backlog of drug files under review. The regulator has not provided specific timelines for individual approvals, noting that generic versions can only be approved after Novo Nordisk's remaining data exclusivity periods end.
The nine applications represent submissions from various pharmaceutical manufacturers seeking to produce biosimilar versions of semaglutide in different strengths and formulations. Each application must demonstrate bioequivalence and manufacturing quality standards equivalent to the original branded products.
Market Impact Expectations
Industry analysts anticipate significant price reductions once generic competition begins. Previous reports have suggested potential price cuts of up to 65% compared to current brand-name pricing, though actual market pricing will depend on competitive dynamics and provincial formulary decisions.
Canada is positioned to become the first major market globally to offer generic semaglutide products, as patent protection remains in place in the United States and other jurisdictions until later in the decade.
Provincial Coverage Considerations
The arrival of generic alternatives will likely prompt provincial drug plans and private insurers to reassess coverage policies. Several provinces have limited coverage of branded GLP-1 medications due to cost considerations, but generic availability could expand access through public formularies.
British Columbia's recent launch of national pharmacare on March 1, 2026, may serve as a model for how generic semaglutide could be incorporated into expanded public drug coverage programs across Canada.
Manufacturing and Supply Chain
The complexity of semaglutide manufacturing presents challenges for generic producers. The medication requires specialized cold-chain distribution and precise manufacturing processes to maintain stability and efficacy. Companies with applications under review include established generic manufacturers with experience in complex biologics production.
Health Canada's approval process will evaluate each manufacturer's ability to maintain consistent quality and supply reliability, factors that proved crucial during previous GLP-1 medication shortages.
Patient and Healthcare System Preparation
Healthcare providers are preparing for the transition to generic alternatives, with some pharmacy chains already indicating plans to stock multiple generic versions once approved. The insurance coverage checker on comparison platforms will need updates to reflect new generic pricing and coverage policies.
Patient advocacy groups have emphasized the importance of ensuring seamless transitions between branded and generic versions, particularly for patients who have achieved stable treatment outcomes on current medications. Our FAQ section addresses common questions about generic medication switches.
Monitoring Generic Development
As the regulatory review process continues, patients and healthcare providers can track developments through Health Canada's public database of submissions under review. The generic semaglutide tracker provides updates on approval timelines and market entry expectations.
The third quarter timeline suggests Canadian patients could see the first generic semaglutide options available between July and September 2026, marking a significant milestone in GLP-1 medication accessibility.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
